MedTrace Logo

TGF β 1 Expression Related Gene Polymorphism

NCT06683690 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-11-12

No results posted yet for this study

Summary

Leprosy is one of the oldest human infectious diseases. It is a chronic infectious contagious, granulomatous disease caused by intracellular bacillus.

Mycobacterium leprae, this chronic granulomatous disease presents symptoms that mainly affected the skin, the nervous system and the reticuloendothelial system, also other systems can be affected, such as the upper respiratory tract, bones and joints, eyes and adrenal glands.

TGF- β is a pleiotropic cytokine that employs several functions on different types of cells. The effect of other cytokines may finally modulate the cellular response in the presence of TGF- β, causing a different effect depending on the activation state of the cell involved. In addition, TGF- β promotes the healing of inflamed tissue through the stimulation and regulation of extracellular matrix by fibroblasts, in addition to inducing the proliferation of endothelial cells required for angiogenesis. Thus, TGF- β is able to regulate the expression of other growth factors, increasing their level of activity.

Conditions

  • Leprosy

Interventions

PROCEDURE

Measurement of TGF- β1 in leprosy patients

Study TGF- β1gene polymorphism in leprosy patients, and Correlate their results with different types of leprosy before and after treatment.

Sponsors & Collaborators

  • Aswan University

    lead OTHER

Principal Investigators

  • Moustafa Adam Ali El Taieb, Professor · Dermatology, Venereology and Andrology. Faculty of Medicine, Aswan University

  • Abdallah Mahmoud Abdallah, Professor · Biochemistry and Molecular Biology. Faculty of Medicine, Aswan University

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-10
Primary Completion
2025-07-05
Completion
2025-07-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06683690 on ClinicalTrials.gov